Edition:
United States

Inovio Pharmaceuticals Inc (INO.OQ)

INO.OQ on NASDAQ Stock Exchange Global Select Market

4.49USD
4:00pm EDT
Change (% chg)

$0.07 (+1.58%)
Prev Close
$4.42
Open
$4.44
Day's High
$4.53
Day's Low
$4.44
Volume
90,545
Avg. Vol
182,178
52-wk High
$7.00
52-wk Low
$3.64

Chart for

About

Inovio Pharmaceuticals, Inc. (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery... (more)

Overall

Beta: 1.67
Market Cap(Mil.): $405.69
Shares Outstanding(Mil.): 90.96
Dividend: --
Yield (%): --

Financials

  INO.OQ Industry Sector
P/E (TTM): -- 169.61 31.56
EPS (TTM): -1.06 -- --
ROI: -75.16 1.42 12.88
ROE: -80.60 0.52 15.04

BRIEF-Inovio Opens Trial To Test Its VGX-3100 Drug In HPV Patients

* INOVIO OPENS PHASE 2 TRIAL FOR VGX-3100 IN THIRD INDICATION TO TREAT HPV – THE NO. 1 SEXUALLY TRANSMITTED DISEASE

May 21 2018

BRIEF-Inovio Says HIV Vaccine Maintained Immune Responses One Year After Start Of Trial

* INOVIO HIV VACCINE, WHICH GENERATED NEAR 100% IMMUNE RESPONSES, SUSTAINED DURABLE MEMORY RESPONSES MEASURED ONE YEAR AFTER THE START OF CLINICAL TRIAL Source text for Eikon: Further company coverage:

May 15 2018

BRIEF-Inovio Pharmaceuticals Q1 Loss Per Share $0.36

* INOVIO PHARMACEUTICALS REPORTS 2018 FIRST QUARTER FINANCIAL RESULTS

May 09 2018

BRIEF-Inovio Pharmaceuticals Says For Qtr Ended March 31, Net Loss Per Share Was $0.36

* INOVIO PHARMACEUTICALS SAYS FOR THREE MONTHS ENDED MARCH 31, 2018, NET LOSS PER SHARE WAS $0.36 - SEC FILING

May 09 2018

BRIEF-Inovio Awarded Up To $56 Million From Cepi To Advance Dna Vaccines Against Lassa Fever And Mers

* INOVIO AWARDED UP TO $56 MILLION FROM CEPI TO ADVANCE DNA VACCINES AGAINST LASSA FEVER AND MERS

Apr 11 2018

BRIEF-Inovio Closes License And Collaboration Agreement With ApolloBio To Develop And Commercialize VGX-3100 In Greater China

* INOVIO CLOSES LICENSE AND COLLABORATION AGREEMENT WITH APOLLOBIO TO DEVELOP AND COMMERCIALIZE VGX-3100 IN GREATER CHINA

Mar 20 2018

BRIEF-Inovio Pharmaceuticals Reports Qtrly ‍Net Loss Attributable To Stockholders Of $0.24 Per Basic Share​

* INOVIO PHARMACEUTICALS REPORTS 2017 FOURTH QUARTER AND YEAR END FINANCIAL RESULTS

Mar 14 2018

BRIEF-Inovio's DNA Immunotherapy Demonstrates Immune Response Results Key In Treating Chronic Hepatitis B Infection

* INOVIO'S DNA IMMUNOTHERAPY DEMONSTRATES IMMUNE RESPONSE RESULTS KEY IN TREATING CHRONIC HEPATITIS B INFECTION Source text for Eikon: Further company coverage:

Mar 14 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $129.50 -0.72
Novartis AG (NOVN.S) CHF81.52 -0.16
Pfizer Inc. (PFE.N) $40.71 -0.10
Merck & Co., Inc. (MRK.N) $66.46 -0.26
Sanofi SA (SASY.PA) €72.85 -0.64
GlaxoSmithKline plc (GSK.L) 1,560.00 +9.20
AstraZeneca plc (AZN.L) 6,015.00 -37.00

Earnings vs. Estimates